Hepatocyte‐Specific Delivery of siRNAs Conjugated to Novel Non‐nucleosidic Trivalent <i>N</i>‐Acetylgalactosamine Elicits Robust Gene Silencing in Vivo
Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Kristina Yucius(Alnylam Pharmaceuticals (United States)), Anna Borodovsky(Brigham and Women's Hospital), Abigail Liebow(Alnylam Pharmaceuticals (United States)), Jennifer L. S. Willoughby(Alnylam Pharmaceuticals (United States)), Muthusamy Jayaraman(Forma Therapeutics (United States)), Nate Taneja(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), William Querbes(Alnylam Pharmaceuticals (United States)), Tuyen Nguyen(Alnylam Pharmaceuticals (United States)), Stuart Milstein(Alnylam Pharmaceuticals (United States)), Jonathan O′Shea(Alnylam Pharmaceuticals (United States)), Kevin Fitzgerald(Epsilon Systems (United States)), Svetlana Shulga‐Morskaya(Alnylam Pharmaceuticals (United States)), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Jayaprakash K. Nair(Alnylam Pharmaceuticals (United States))
Cited by 184
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
|Nature Biotechnology|2008|1.2k